Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05234177 · ClinicalTrials.gov registry record
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
A clinical trial of Colorectal Cancer, sponsored by Tempus AI.
- Recruiting
- Registry status
- 300
- Enrollment target
- 20
- Study locations
NCT05234177: Recruiting study of Colorectal Cancer, sponsored by Tempus AI.
NCT05234177 is a study of Colorectal Cancer that is actively recruiting participants, run by Tempus AI. The registered enrollment target is 300 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05234177, a study of Colorectal Cancer, is actively recruiting participants, sponsored by Tempus AI.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.
Primary Outcome
Recurrence-Free Survival as assessed by standard radiographic imaging, measured from the day of completion of definitive treatment to first radiographic recurrence or death
Conditions Studied
Interventions
- OTHER Observation
Study Locations (20)
Missouri
- Mercy Clinic Oncology and Hematology - Joplin - Joplin
- Mercy Clinic Cancer and Hematology - Chub O'Reilly Cancer Center - Springfield
- Washington University School of Medicine - St Louis
- Mercy Clinic Oncology and Hematology - Sindelar Cancer Center - St Louis
- Mercy Clinic Oncology and Hematology - David C. Pratt Cancer Center - St Louis
Ohio
- Aultman Hospital - Canton
- TriHealth Cancer Institute - Cincinnati
- Ohio State University - Columbus
- OhioHealth Research Institute - Columbus
- Toledo Clinic Cancer Center - Toledo
Arkansas
- Mercy Clinic Oncology - Fort Smith - Fort Smith
California
- MemorialCare - Fountain Valley
Maryland
- The Center for Cancer and Blood Disorders - Bethesda
Nebraska
- Nebraska Cancer Specialists - Omaha
North Carolina
- Southeastern Medical Oncology Center - Goldsboro
Oklahoma
- Mercy Clinic Oncology and Hematology - Coletta - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2022-06-21 |
| Est. Completion | 2029-02 |
What NCT05234177 shows while recruiting
NCT05234177 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which Observation is the first listed.
NCT05234177 names 20 study sites across 12 states, led by Missouri, Ohio, Arkansas.
Frequently Asked Questions
What is clinical trial NCT05234177 about?
NCT05234177 is a clinical study titled "Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays". The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.
What is the current status of trial NCT05234177?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2022-06-21. Estimated completion is 2029-02.
What conditions does trial NCT05234177 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT05234177?
The interventions under investigation include: Observation (OTHER).
Who is sponsoring clinical trial NCT05234177?
This trial is sponsored by Tempus AI, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05234177 being conducted?
This trial has 20 study locations across Arkansas, California, Maryland, Missouri, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05234177's enrollment target sits among peer trials
300 110th of 381 higher than 267 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI